wnt/β-catenin在肺炎支原体肺炎纤维素形成机制探讨及与TGF-β交互作用和芩百对其干预研究

芩百清肺浓缩丸是第一个用于临床观察明确治疗小儿肺炎支原体肺炎的中药新药。临床研究报告显示芩百治疗肺炎支原体肺炎疗效确切。前期实验研究显示芩百浓缩丸能有效抑制间质性肺炎、细支气管肺炎。然而在确切疗效基础上，其作用机制尚不明确，制约了该药疗效的提高和深度开发。本项目以芩百清肺浓缩丸为研究对象，以其对肺炎支原体感染后抑制肺纤维蛋白分泌为出发点，从分子水平上直接阐明细胞因子及信号通路分子调控机制，研究关键基因的调控网络，解析其作用的靶点。即采用Real-timePCR、WesternBlot、免疫荧光、磷酸化等技术，通过Wnt/β-catenin和TGF-β交互作用及EMT变化阐明芩百清肺浓缩丸抑制肺炎支原体肺炎纤维蛋白分泌的作用机制，为该新药的疗效提高和深度开发提供理论和实验根据，亦为中药更好发挥防治肺炎支原体作用提供支撑。

Qinbaiqingfei pellet is first clinical Traditional Chinese Medicine treating children mycoplasmal pneumonia. Clinical research sport of SFDA show its integrated curative effect. Earlier study show that Qinbaiqingfei pellet can inhibit interstitial pneumonia and bronchopneumonia. Uncertainty mechanism restrict a raising of therapeutic effect and deep development, so we try to research Wnt/β-catenin、TGF-β cell signaling mechanisms and EMT effect of Qinbaiqingfei pellet inhibiting the secretion of lung fibrin Induced by Mycoplasma Pneumoniae Infection by Real-time PCR、WesternBlot、 immunofluorescence and phosphorylation. It is bound to be of great service on treating Mycoplasma Pneumoniae of Traditional Chinese Medicine.